The prognostic value of MELD-XI in elderly patients with ST-segment elevation myocardial infarction: an observational study

Early diagnosis and intervention have dramatically improved the prognosis of ST-segment elevation myocardial infarction (STEMI) [1, 2]. However, the mortality from STEMI remains high in elderly patients. Epidemiological data have indicated that the estimated one-year mortality in elderly patients with STEMI undergoing percutaneous coronary intervention (PCI) is 10% and continues to increase with age [3‐5]. The Thrombolysis In Myocardial Infarction (TIMI) risk score is a guideline-recommended, risk-stratified tool for STEMI patients [6]. Nevertheless, this score is not established specially for elderly patients. Previous studies have shown that the area under the curve (AUC) of TIMI risk score was only 0.71 for predicting in-hospital mortality and 0.67 for 30-day mortality [7, 8] in elderly patients with STEMI. Therefore, improving the predictive accuracy is necessary for these patients.

Aging represents the progressive functional decline in a variety of organ systems that occurs with advancing time [9]. Renal and liver dysfunction were common in elderly patients with myocardial infarction, which were associated with poor prognosis [10, 11]. The model for end-stage liver disease excluding international normalized ratio (MELD-XI) score is a novel and simple score to simultaneously assess liver and kidney function [12]. This scoring model exhibited excellent predictive power in critically ill patients [13, 14]. However, the association of MELD-XI with adverse events has not been reported in STEMI patients. Therefore, this study was performed to investigate the prognostic value of MELD-XI in elderly patients with STEMI undergoing PCI and determine whether adding MELD-XI to the TIMI risk score enhances the prediction of in-hospital and one-year death.

In all, 1029 STEMI patients were included, and were divided into three groups according to the TIMI risk score: low risk (≤ 3, n = 251); moderate risk (4–6, n = 509); and high risk (≥ 7, n = 269). The clinical characteristics according to different risk status were showed in Table 1. Patients in the high-risk group were more likely to be female. The high-risk group showed higher serum creatinine, alanine transaminase (ALT), and total bilirubin levels and lower hemoglobin and LVEF than the other two groups. The rate of intra-aortic balloon pump (IABP) placement was higher in patients with a high TIMI risk score. In addition, prolonged hospitalization was observed in these patients.

55 (5.3%) patients died while in hospital, 42 of which died from cardiac disease. Other causes of death included infection, cerebral hernia and multiple organ failure. A higher in-hospital all-cause mortality (1.2% vs. 3.3% vs. 13.0%, p < 0.001), cardiac mortality (1.2% vs. 2.6% vs. 9.7%, p < 0.001) and MACEs (5.6% vs. 10.8% vs. 24.2%, p < 0.001) were found in patients with high TIMI risk score than the low- and medium-risk groups. The ROC curve showed that MELD-XI ≥ 13 had a sensitivity of 63.6% and specificity of 80.2% for predicting in-hospital all-cause death (AUC = 0.750, 95% CI = 0.684–0.816, p < 0.001, Fig. 1). The AUC of TIMI risk score was 0.753 and the optimal cut-off was 7. No statistically significant difference was found on comparing their discriminatory abilities.

Multivariate logistic regression analysis indicated that MELD-XI was independently associated with in-hospital all-cause death even after adjusting for TIMI risk score, log(creatine kinase MB), ALT > 40 U/L, LVEF, and IABP treatment (OR = 1.09, 95% CI = 1.04–1.14, p = 0.001, Table 2). A similar result was seen when we included MELD-XI ≥ 13 instead of MELD-XI as a continuous variable in model 2 (OR = 3.83, 95% CI = 1.99–7.40, p < 0.001, Table 2). Therefore, we added four points into the TIMI risk score when MELD-XI ≥ 13 according to the adjusted OR. Combining TIMI risk score and MELD-XI exhibited better predictive power for in-hospital all-cause death than the TIMI risk score (AUC: 0.810 vs. 0.753, p = 0.008, Fig. 1a) or MELD-XI alone (AUC: 0.810 vs. 0.750, p = 0.018, Fig. 1a). Similar result was found in cardiac mortality (Fig. 1b).

In total, 109 (10.6%) patients died during the one-year follow-up period. Multivariate Cox regression analysis showed that MELD-XI was a predictor for one-year mortality independent of the TIMI risk score (HR = 1.17, 95% CI = 1.07–1.27, p < 0.001, Table 3). Other significant risk factors included LVEF and IABP treatment.

Patients were reclassified into four groups according to the cut-off of TIMI risk score and MELD-XI: TIMI risk score ≥ 7 and MELD-XI ≥ 13 (n = 99), TIMI risk score ≥ 7 and MELD-XI < 13 (n = 170), TIMI risk score < 7 and MELD-XI ≥ 13 (n = 143), and TIMI risk score < 7 and MELD-XI < 13 (n = 617). The in-hospital all-cause mortality (25.3%), cardiac mortality (19.6%) and incidence of MACEs (40.4%) were highest in the group of patients with TIMI risk score ≥ 7 and MELD-XI ≥ 13 (both p < 0.001, Fig. 2). The Kaplan–Meier curve showed that a higher accumulative one-year mortality was found in patients with TIMI risk score ≥ 7 and MELD-XI ≥ 13 (log-rank = 98.35, p < 0.001, Fig. 3). Multivariate analysis revealed that compared with TIMI risk score < 7 and MELD-XI < 13, TIMI risk score ≥ 7 and MELD-XI ≥ 13 were independently associated with in-hospital (OR = 11.06, 95% CI = 4.38–27.96, p < 0.001, Table 4), cardiac (OR = 14.09, 95% CI = 4.59–43.27, p < 0.001, Table 4) and one-year mortality (HR = 4.20, 95% CI = 2.24–7.87, p < 0.001, Table 4).

The present study showed that MELD-XI was an independent risk factor for in-hospital and one-year mortality after adjusting for TIMI risk score and other potential confounding factors in elderly patients with STEMI undergoing PCI. To our best knowledge, this study is the first to explore the additional prognostic value of MELD-XI to TIMI risk score. Combining TIMI risk score and MELD-XI exhibited better predictive power for in-hospital death than the TIMI risk score or MELD-XI alone. Patients with TIMI risk score ≥ 7 and MELD-XI ≥ 13 had the worst prognosis.

The TIMI risk score was first developed in the era of thrombolytic therapy and has high discriminative ability for adverse events in STEMI patients [16]. Wei et al. reported that the AUC of the TIMI risk score for predicting in-hospital mortality was 0.803 [19]. In addition, its discriminative ability was adequate for clinical application in STEMI patients undergoing primary PCI (c-statistic, > 0.8) [20]. Accordingly, this score was also recommended for early risk assessment in STEMI patients in the era of primary PCI [6]. However, its predictive power is insufficient in elderly patients. A previous study showed that the prognostic discrimination and calibration of TIMI risk score for the 30-day mortality was not high in elderly patients with STEMI (AUC = 0.67) [7]. Similar results were found in female patients with STEMI [8]. In our study, the AUC of TIMI risk score for predicting in-hospital death was 0.753. Therefore, it is necessary to identify other risk factors to improve the discriminative ability of TIMI risk score.

The MELD score consists of serum creatinine and bilirubin levels and the international normalized ratio (INR), which is established for patients with end-stage liver disease [21]. MELD-XI excluding INR is a simpler risk model that can simultaneously assess renal and liver function [12]. It has already been validated in other conditions. In patients with heart failure, MELD-XI was related to increased risk of death at the one-year follow-up [22]. The AUC of MELD-XI for predicting adverse events at the one-year follow-up was 0.69 in patients undergoing tricuspid annuloplasty [23]. In critically ill patients, MELD-XI represented organ failure and was associated with in-hospital mortality [24].

Elevated serum creatinine and bilirubin are established risk factors for poor prognosis in STEMI patients [25, 26]. Although MELD is reportedly a predictor of long-term survival in patients with acute coronary syndrome undergoing PCI, the prognostic value of MELD-XI is not yet clear [27]. Therefore, we carried out this study, the results of which showed that MELD-XI has similar predictive power as TIMI risk score in elderly patients with STEMI undergoing PCI. In addition, MELD-XI was associated with in-hospital and 1-year mortality even after adjusting for TIMI risk score and other confounding factors. Renal and hepatic function are not included elements in the TIMI risk score. Accordingly, the combination of MELD-XI and TIMI risk scores showed high predictive power for in-hospital and one-year mortality, which could be a potentially useful tool for risk assessment in elderly patients with STEMI undergoing PCI.

The present study has some limitations. First, clinical variables were limited owing to the retrospective study design. Second, although multivariate analysis was conducted, residual confounders might have still affected our results. Third, this study was conducted in elderly patients with STEMI undergoing PCI; therefore, it remains to be seen whether these conclusions can be extrapolated to other age groups. Finally, this study was a single-center study and thus external validity of results has not been measured.

Our study demonstrated that MELD-XI could predict in-hospital and one-year mortality in elderly patients with STEMI undergoing PCI. The discriminative ability of MELD-XI for in-hospital death was equal to that of the TIMI risk score. MELD-XI could provide additional prognostic value to the TIMI risk score. Therefore, it may be clinically useful to combine the MELD-XI and TIMI risk scores for risk assessment in elderly patients with STEMI undergoing PCI.